388 related articles for article (PubMed ID: 8637215)
1. Myelodysplastic syndromes in the elderly: the role of growth factors in management.
Saba HI
Leuk Res; 1996 Mar; 20(3):203-19. PubMed ID: 8637215
[TBL] [Abstract][Full Text] [Related]
2. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
[TBL] [Abstract][Full Text] [Related]
3. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin.
Economopoulos T; Mellou S; Papageorgiou E; Pappa V; Kokkinou V; Stathopoulou E; Pappa M; Raptis S
Leukemia; 1999 Jul; 13(7):1009-12. PubMed ID: 10400415
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic values of in vitro culture growth patterns of marrow granulocyte-macrophage progenitors in patients with myelodysplastic syndrome.
Shih LY; Chiu WF; Lee CT
Leukemia; 1991 Dec; 5(12):1092-8. PubMed ID: 1774958
[TBL] [Abstract][Full Text] [Related]
5. Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodysplastic syndromes: comparison between recombinant human granulocyte colony-stimulating factor (CSF) and granulocyte-monocyte CSF.
Nagler A; Binet C; Mackichan ML; Negrin R; Bangs C; Donlon T; Greenberg P
Blood; 1990 Oct; 76(7):1299-307. PubMed ID: 1698477
[TBL] [Abstract][Full Text] [Related]
6. Measurement of serum cytokine levels in patients with myelodysplastic syndromes.
Verhoef GE; De Schouwer P; Ceuppens JL; Van Damme J; Goossens W; Boogaerts MA
Leukemia; 1992 Dec; 6(12):1268-72. PubMed ID: 1280751
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
Kasper C; Zahner J; Sayer HG
J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
[TBL] [Abstract][Full Text] [Related]
8. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
[TBL] [Abstract][Full Text] [Related]
9. The Myelodysplastic Syndromes.
Cheson BD
Oncologist; 1997; 2(1):28-39. PubMed ID: 10388027
[TBL] [Abstract][Full Text] [Related]
10. Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodysplastic syndromes.
Asano H; Hotta T; Ichihara M; Murate T; Kobayashi M; Saito H
Leukemia; 1994 May; 8(5):833-8. PubMed ID: 7514249
[TBL] [Abstract][Full Text] [Related]
11. Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases.
Foucar K; Langdon RM; Armitage JO; Olson DB; Carroll TJ
Cancer; 1985 Aug; 56(3):553-61. PubMed ID: 3891071
[TBL] [Abstract][Full Text] [Related]
12. Revisiting use of growth factors in myelodysplastic syndromes.
Newman K; Maness-Harris L; El-Hemaidi I; Akhtari M
Asian Pac J Cancer Prev; 2012; 13(4):1081-91. PubMed ID: 22799286
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
Wimazal F; Krauth MT; Vales A; Böhm A; Agis H; Sonneck K; Aichberger KJ; Mayerhofer M; Simonitsch-Klupp I; Müllauer L; Sperr WR; Valent P
Leuk Lymphoma; 2006 Mar; 47(3):451-60. PubMed ID: 16396768
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes.
Neubauer A; Greenberg P; Negrin R; Ginzton N; Liu E
Leukemia; 1994 Apr; 8(4):638-41. PubMed ID: 7512175
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome.
Jädersten M; Malcovati L; Dybedal I; Della Porta MG; Invernizzi R; Montgomery SM; Pascutto C; Porwit A; Cazzola M; Hellström-Lindberg E
J Clin Oncol; 2008 Jul; 26(21):3607-13. PubMed ID: 18559873
[TBL] [Abstract][Full Text] [Related]
16. Hypoplastic myelodysplastic syndrome.
Nand S; Godwin JE
Cancer; 1988 Sep; 62(5):958-64. PubMed ID: 3409176
[TBL] [Abstract][Full Text] [Related]
17. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.
Hellström-Lindberg E; Ahlgren T; Beguin Y; Carlsson M; Carneskog J; Dahl IM; Dybedal I; Grimfors G; Kanter-Lewensohn L; Linder O; Luthman M; Löfvenberg E; Nilsson-Ehle H; Samuelsson J; Tangen JM; Winqvist I; Oberg G; Osterborg A; Ost A
Blood; 1998 Jul; 92(1):68-75. PubMed ID: 9639501
[TBL] [Abstract][Full Text] [Related]
18. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
Aul C; Gattermann N; Heyll A; Germing U; Derigs G; Schneider W
Leukemia; 1992 Jan; 6(1):52-9. PubMed ID: 1736014
[TBL] [Abstract][Full Text] [Related]
19. Clinical use of hematopoietic growth factors in patients with myelodysplastic syndromes.
Geissler RG; Schulte P; Ganser A
Int J Hematol; 1997 Jun; 65(4):339-54. PubMed ID: 9195774
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
